北京中医药大学学报2016，Vol.39Issue(7)：595-604,10.DOI:10.3969/j.issn.1006-2157.2016.07.014
参附注射液治疗缓慢性心律失常的有效性和安全性研究：随机对照试验的系统评价和Meta分析
Efficacy and safety of Shenfu injection treating bradycardia:a systematic review with meta-analysis of randomized controlled trials
摘要
Abstract
Objective To evaluate the efficacy and safety of Shenfu injection in the treatment of brady-cardia.Methods Randomized controlled trials (RCT) on Shenfu injection treating bradycardiawas re-trieved from CNKI database, Wanfang Database,VIP Database,CBM,PubMed, EMbase, and Clinical Trials.gov.Cochrane Handbook was used to assess methodological quality , and data were analyzed using RevMan5 .3 Software .Results 13 trials involving 978 patients were included into the analysis .The over-all methodological quality was low as most studies were evaluated as B level and one study was C level . Meta-analysis showed that Shenfu injection was better than atropine (RR=1.27, 95%CI 1.09~1.48, P=0.002)in terms of the overall effect (relief of symptoms and improvement of heart rate ), but there were no statistic difference between using atropine alone andusing Shenfu injection and atropine together (RR=0.84, 95%CI 0.73~0.97, P=0.30).Compared with Shenfu injection in polarized solution, Shenfu injection can improve the clinical symptoms better (RR=0.52, 95%CI 0.40~0.67, P=0.01), but there was no difference in the heart rate increase (RR=0.57,95%CI 0.32 ~1.20,P=0.06). Safety:Adverse reactions were reported in four studies , with dry mouth being the most common one . Conclusion In view of the quality of the current research , the efficacy of treating bradycardia with Shen-fu injection cannot be ensured .In the future , high quality studies are needed to confirm the efficacy of Shenfu injection .关键词
参附注射液/缓慢性心律失常/系统评价/循证医学Key words
Shenfu injection/bradycardia/systematic review/evidence-based medicine分类
医药卫生引用本文复制引用
章轶立,贾敏,谢雁鸣,廖星,王凤姣..参附注射液治疗缓慢性心律失常的有效性和安全性研究：随机对照试验的系统评价和Meta分析[J].北京中医药大学学报,2016,39(7):595-604,10.基金项目
＃中央级公益性科研院所基本业务费项目（No．Z0406，No．PY1303），2014年第七批博士后特别资助 （）
